Literature DB >> 11268453

Expression of the neutral amino acids transporter ASCT1 in esophageal carcinomas.

M Younes1, M Pathak, D Finnie, R N Sifers, Y Liu, M R Schwartz.   

Abstract

Cancers cells utilize more glucose and amino acids than their benign counterparts. Overexpression of the facilitative glucose transporter Glut1 in human cancers was found to correlate with aggressive biologic behavior. The aim of this work was to determine whether the neutral amino acid transporter ASCT1 is expressed in human esophageal carcinomas, and to correlate the findings with Glut1 expression. Sections of formalin-fixed and paraffin-embedded tissue from 42 cases of esophageal carcinomas were entered in the study. Immunohistochemical staining was performed using a rabbit anti-ASCT1 IgG developed in our laboratory, and anti-Glut1 antibody, using standard avidin-streptavidine immunoperoxidase method. Sections of formalin-fixed and paraffin-embedded HepG2 cells were used as positive controls. The percent of ASCT1-positive cells was scored. Statistical analysis was performed using Fisher's exact test. ASCT1 immunoreactivity was cytoplasmic, whereas Glut1 was membranous. Significantly more adenocarcinomas expressed ASCT1 than squamous cell carcinomas (p < 0.0001), whereas Glut1 expression was similar in both tumor types. There was no association between the expression of either transporter and lymph node metastasis. Glut1 was expressed more often in the better differentiated than the poorly differentiated squamous carcinomas (p = 0.003). These results suggest that unlike in squamous cell carcinoma, ASCT1 plays a significant role in the recruitment of amino acids in adenocarcinoma of the esophagus, and suggest that the metabolic needs, and uptake of nutrients, are regulated differently in these two tumor types. Additional studies with larger number of patients are needed to determine the biological significance of ASCT1 expression in esophageal carcinomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11268453

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression.

Authors:  S Weis; I C Llenos; J R Dulay; N Verma; S Sabunciyan; R H Yolken
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

2.  Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively.

Authors:  Nikolaos Charalampakis; Lianchun Xiao; Elena Elimova; Roopma Wadhwa; Hironori Shiozaki; Yusuke Shimodaira; Mariela A Blum; Venkatram Planjery; Jane E Rogers; Aurelio Matamoros; Tara Sagebiel; Prajnan Das; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Jeannelyn S Estrella; Brian D Badgwell; Jaffer A Ajani
Journal:  Oncology       Date:  2015-09-23       Impact factor: 2.935

3.  Prediction-Oriented Marker Selection (PROMISE): With Application to High-Dimensional Regression.

Authors:  Soyeon Kim; Veerabhadran Baladandayuthapani; J Jack Lee
Journal:  Stat Biosci       Date:  2016-09-26

4.  Upregulated SLC1A5 promotes cell growth and survival in colorectal cancer.

Authors:  Fang Huang; Yingchao Zhao; Junzhang Zhao; Shuang Wu; Yao Jiang; Hong Ma; Tao Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 5.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

6.  L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma.

Authors:  Jules Lin; Duna A Raoof; Dafydd G Thomas; Joel K Greenson; Thomas J Giordano; Gregory S Robinson; Maureen J Bourner; Christopher T Bauer; Mark B Orringer; David G Beer
Journal:  Neoplasia       Date:  2004 Jan-Feb       Impact factor: 5.715

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.